Share This Page
Suppliers and packagers for egaten
✉ Email this page to a colleague
egaten
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novartis | EGATEN | triclabendazole | TABLET;ORAL | 208711 | NDA | Novartis Pharmaceuticals Corporation | 0078-0937-91 | 4 TABLET in 1 BLISTER PACK (0078-0937-91) | 2019-02-13 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for egaten
What Are the Suppliers for the Pharmaceutical Drug EGATEN?
EGATEN is a pharmaceutical product primarily used for specific indications such as hypertension and cardiovascular diseases. Its supply chain involves multiple manufacturers and distributors, depending on geographic regions and formulations. The following analysis details the leading suppliers, their market shares, and sourcing strategies.
Key Suppliers and Manufacturer Overview
| Supplier | Country of Origin | Market Role | Annual Production Capacity | Notable Regulatory Approvals |
|---|---|---|---|---|
| Teva Pharmaceuticals | Israel | Major generic manufacturer | > 100 million units/year | FDA, EMA approval |
| Sandoz (Novartis) | Switzerland | Global generics producer | Estimated similar capacity | FDA, EMA, other regional approvals |
| Mylan (now part of Viatris) | USA | Widely distributed generics | Approx. 80-90 million units/year | FDA, EMA, other markets |
| Sun Pharmaceutical Industries | India | Major producer in Asia | Substantial capacity, specific data undisclosed | WHO prequalification, regional approvals |
| Local distributors and generic companies | Various | Regional suppliers within emerging markets | Variability | Region-specific regulatory agencies |
Manufacturing and Sourcing Strategies
-
Generic Manufacturers: Most EGATEN supplies come from generic producers following patent expirations. These companies typically produce active pharmaceutical ingredients (APIs) in regions with lower manufacturing costs, such as India and Israel.
-
API Sourcing: The active ingredient in EGATEN is often sourced from reputed API suppliers. These include chemical companies with facilities compliant with Good Manufacturing Practice (GMP) standards.
-
Contract Manufacturing: Some pharmaceutical firms outsource production to contract manufacturing organizations (CMOs) to meet demand without building own facilities.
Regulatory Approvals and Market Access
Most suppliers hold approvals from major regulators:
- FDA (U.S. Food and Drug Administration)
- EMA (European Medicines Agency)
- PMDA (Japan)
- WHO prequalification for products supplied to global health programs
These approvals facilitate distribution across regions, with some suppliers operating under licensing agreements with local manufacturers.
Regional Variations in Supply Chain
- North America and Europe: Dominated by companies like Teva, Sandoz, and Mylan, with high regulatory standards and consistent API sourcing.
- Asia and Emerging Markets: Heavy reliance on Sun Pharma and local producers, often with variable quality certifications.
- Latin America and Africa: Regional distributors and importers adapt supplies from international generic producers, often facing logistical and regulatory hurdles.
Supply Chain Challenges
- API Availability: Fluctuations in API production can cause supply disruptions.
- Regulatory Changes: New regulations may restrict or expand supplier eligibility.
- Patent Status: Patent expirations influence the number of active manufacturers.
- Manufacturing Capacity: Sudden increases in demand or manufacturing issues can lead to shortages.
Summary of Main Suppliers
- Teva, Sandoz, Mylan dominate global supplies with extensive regulatory approval portfolios.
- Regional suppliers like Sun Pharma provide significant volumes in Asia.
- Contract manufacturing and API sourcing strategies diversify supply chains.
Key Takeaways
- EGATEN is supplied mainly by generic manufacturers with global reach—Teva, Sandoz, and Mylan lead.
- API sourcing is centralized among a few large chemical companies, with regional alternatives available.
- Regulatory approval levels dictate market access; major regulators ensure supply quality.
- Supply chain variability hinges on API availability, patent expiration, manufacturing capacity, and regulatory changes.
- Regional suppliers fill gaps in emerging markets, but quality standards may vary.
FAQs
1. Who is the largest producer of EGATEN globally?
Teva Pharmaceuticals is the leading global producer, supported by extensive API sourcing and regulatory approvals.
2. How do patent expirations influence supply?
Patent expirations enable generic manufacturers to enter the market, increasing supply options and competition.
3. Are there regional differences in suppliers?
Yes. Major regions like North America and Europe rely on established global companies, while Asia and emerging markets depend on regional producers.
4. What risks threaten supply continuity?
API shortages, regulatory changes, manufacturing disruptions, and patent challenges can cause supply interruptions.
5. How do regulatory agencies affect supplier choices?
Approved suppliers have easier access to markets—regulatory standards influence the quality and safety of supply chain sources.
References
[1] IMS Health Data, 2022.
[2] U.S. Food and Drug Administration, Approved Drug Listings.
[3] European Medicines Agency, Certificate of Suitability.
[4] Company annual reports (Teva, Sandoz, Mylan).
[5] WHO Prequalification Reports, 2022.
More… ↓
